Larimar Therapeutics Inc
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Larimar Therapeutics' stock as it has significant potential for growth.
Financial Health
Larimar Therapeutics is showing solid financial performance with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LRMR
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial readouts and regulatory steps can materially affect value; positive data may drive interest, though outcomes are uncertain and volatile.
Development Focus
Progress depends on scientific results and execution; strong data can open partnership or commercial options, but setbacks are possible.
Monitor Funding Needs
Small biotechs often require further capital to fund trials, which can dilute shareholders; check filings for cash runway and financing plans.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
